[4] GELATTI A C Z,DRILON A,SANTINI F C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor ( EGFR) mutation-positive non-small cell lung cancer (NSCLC)[J]. Lung Cancer,2019,137: 113 - 122. [5] AKBAY E A,KOYAMA S,CARRETERO J,et al....
英文标题:A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation. 中文标题:TY-9591治疗EGFR突变的晚期NSCLC的I期研究。 讲者:B. Han (上海交通大学医学院附属上海胸科...
[13] Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised pha...
这是一项来自荷兰的研究，只有 8个肺癌病人 ，都是 EGFR基因突变。使用EGFR靶向药物之后出现了耐药，经过二代基因检测以及原文免疫荧光杂交（FISH）确定了是MET基因扩增。这些患者有的使用过一代或二代药物，有的使用过三代药物，还有中间经过铂类化疗的，总之这8个病人虽然数量不多，但是基本上反映了现实中的治疗情...
12. Kobayashi S, Boggon T J, Dayaram T, et al. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. New England Journal of Medicine, 2005, 352(8): 786-792. 13. Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenoca...
[6]Park K, Tan EH, OByrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology. 2016;17(5):577-589. ...
[7]Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study[J]. Lancet Respir ...
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer(FURLONG): a multicentre,double-blind,randomised phase 3 study[J]. Lancet Respir Med,2022,10(11):1019-1028. [15] SHI Y K...
[1]Park K, Tan EH, O'Byrne K et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a Phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17(5), 577–589 (2016) ...
1,Wang J et al. (2022) Adjuvant osimertinib in patients with stage IB–IIIA EGFR mutation-positive NSCLC after complete tumour resection: ADAURA China subgroup analysis. Poster presented at the 2022 European Lung Cancer Conference, Prague, The Czech Republic ...